CHARLESSON, LLP

Basic Information

800 Research Parkway
OKLAHOMA CITY, OK, 73104-3611

Company Profile

n/a

Additional Details

Field Value
DUNS: 143171531
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: Y
Number of Employees: 10


  1. A Wnt Modulator for Treatment of Age-related Macular Degeneration

    Amount: $225,000.00

    PROJECT SUMMARY/ABSTRACT Age-related macular degeneration (AMD) is characterized by progressively decreased central vision and visual acuity and remains a leading cause of vision loss and blindness i ...

    SBIR Phase I 2014 Department of Health and Human Services
  2. Developing A Novel Therapy for Diabetic Retinopathy

    Amount: $246,418.00

    DESCRIPTION (provided by applicant): Diabetic retinopathy (DR) is a common complication of diabetes and a leading cause of vision loss in the United States. Unfortunately, there is no FDA-approved pha ...

    SBIR Phase I 2013 Department of Health and Human Services
  3. A Small Molecule Targeting Wnt Pathway for Treatment of Diabetic Retinopathy

    Amount: $231,087.00

    DESCRIPTION (provided by applicant): Diabetic retinopathy (DR) is a common complication of diabetes and a leading cause of blindness. This sight-threatening condition has become a public health challe ...

    SBIR Phase I 2012 Department of Health and Human Services
  4. Multitargeted Therapy for Age-related Macular Degeneration

    Amount: $265,992.00

    DESCRIPTION (provided by applicant): Age-related macular degeneration (AMD) is a sight-threatening disease which represents the leading cause of blindness and visual impairment in elderly individu ...

    SBIR Phase I 2011 Department of Health and Human Services
  5. Novel emulsion-based formulation of the anti-glaucoma MSH-1001 for improved topic

    Amount: $287,947.00

    DESCRIPTION (provided by applicant): This Small Business Innovation project aims to develop an innovative eye drop formulation for the treatment of glaucoma and ocular hypertension. Charlesson has acq ...

    SBIR Phase I 2011 Department of Health and Human Services
  6. Safety and Toxicology Studies of CLT-005 as a Therapeutic for Diabetic Macular Ed

    Amount: $2,685,795.00

    DESCRIPTION (provided by applicant): The objective of this proposal is to finalize development of CLT-005, a novel small molecule inhibitor of Stat3, through the performance of studies required fo ...

    SBIR Phase II 2011 Department of Health and Human Services
  7. Novel Antioxidants for Treatment of Diabetic Retinopathy

    Amount: $248,094.00

    DESCRIPTION (provided by applicant): Diabetic retinopathy is a common complication of diabetes mellitus and a leading cause of severe vision loss and blindness around the world. The current interventi ...

    SBIR Phase I 2009 Department of Health and Human Services
  8. Development of a novel anti-inflammatory treatment for clinical management of end

    Amount: $227,286.00

    DESCRIPTION (provided by applicant): The objective of this proposal is to examine the efficacy of CLT-005 in reducing ocular inflammation and that occurs during endophthalmitis. Endophthalmitis occurs ...

    SBIR Phase I 2009 Department of Health and Human Services
  9. Sustained delivery of linomide-5 for diabetic retinopathy and macular degeneratio

    Amount: $1,388,677.00

    DESCRIPTION (provided by applicant): Linomide is a known anti-inflammatory drug. Recently we have synthesized a new analog of Linomide, linomide-5. The objective of this proposal is to develop linomid ...

    SBIR Phase II 2008 Department of Health and Human Services
  10. Development of a genetic CNV model for Age-Related Macular Degeneration

    Amount: $210,357.00

    DESCRIPTION (provided by applicant): The objective of this proposal is to develop a service for the high-throughput drug screening of compounds to treat Age-Related Macular Degeneration (AMD). In our ...

    SBIR Phase I 2008 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government